Showing 1501-1510 of 19295 results for "".
ISDPA: Dr. Bhatia on JAK Inhibitors
https://practicaldermatology.com/conferences/isdpa-midwest-derm-2024/isdpa-dr-bhatia-jak-inhibitors/27064/Practical Dermatology Chief Medical Editor Neal Bhatia, MD, FAAD, talks about his presentation on JAK inhibitors at the Illinois Society of Dermatology Physician Assistants (ISDPA) Midwest Dermatology Conference 2024."A big revolution is coming in ultrasound," says Dr. Clément Papadacci from Inserm
https://reachmd.com/programs/the-convergence/ultrasound-clement-papadacci-inserm/39926/4D ultrasound and ultrasound localization microscopy (ULM) are reshaping non-invasive imaging, allowing clinicians to visualize entire organs—down to vessels smaller than a human hair—in dynamic, real-time detail. Dr. Clément Papadacci joins Dr. Brian McDonough to share how his groundbreaking probeAdjuvant Nivolumab in High-Risk Muscle Invasive Urothelial Carcinoma: 5-Year Data
https://reachmd.com/programs/project-oncology/adjuvant-nivolumab-in-high-risk-muscle-invasive-urothelial-carcinoma/36306/Five years after treatment, the impact of adjuvant nivolumab still holds strong in high-risk muscle invasive urothelial carcinoma. Join Drs. Brian McDonough and Matthew Galsky as they review the CheckMate 274 trial’s long-term data, which show sustained disease-free survival and highlight ctDNA’s poImmunotherapy Advances in Early-Stage Upper GI Cancers: Key Trial Insights
https://reachmd.com/programs/project-oncology/immunotherapy-advances-in-early-stage-upper-gi-cancers/35503/Early-stage upper GI cancers carry a high risk of systemic spread, prompting a shift from conventional therapies to immunotherapy-based strategies. Given this evolving landscape, Dr. Ronan Kelly joins Dr. Jennifer Caudle to review landmark trials, including CheckMate 577 and MATTERHORN. Together, thHow Selective Photothermolysis Was Introduced in Dermatology
https://reachmd.com/programs/modern-aesthetics-focus-on-energy-based-devices/talking-fractional-lasers-with-the-inventor/56541/Laser pioneer R. Rox Anderson, MD, FAAD, joins Modern Aesthetics March/April Guest Medical Editor Jill Waibel, FACS, FAAD, to discuss the invention of fractional lasers and the impact of that technology on the field.Bringing Cancer Care Home: How Subcutaneous Immunotherapy Can Help Ease the Burden
https://reachmd.com/programs/project-oncology/bringing-cancer-care-home-how-subcutaneous-immunotherapy-can-help-ease-the-burden/35770/As immunotherapy becomes a cornerstone for treating a growing number of solid tumors, reducing the logistical burden of in-office care is essential. Fortunately, the at-home administration of subcutaneous formulations of immunotherapy agents like atezolizumab could help transform the way we care forComprehensive Care: Navigating Neurobehavioral Issues in DMD Patients
https://reachmd.com/programs/neurofrontiers/comprehensive-care-navigating-neurobehavioral-issues-in-dmd-patients/16502/Here are some best practices for managing the 70 percent of patients with Duchenne muscular dystrophy who also have a neurobehavioral issue.Improving Shingles Vaccination Uptake Through Effective Patient Counseling
https://reachmd.com/programs/vaccination/shingles-vaccination-uptake-patient-counseling/54089/Shingles prevention remains underutilized despite its significant burden in adults aged 50 and older, making effective patient counseling essential in routine care. Given this importance, Dr. Teena Chopra joins Dr. Alexandria May to share practical communication strategies for normalizing shingles vStrengthening Global Infrastructure for FSHD Trials
https://reachmd.com/programs/Audioabstracts/global-infrastructure-fshd-trials/54642/As global clinical trials for facioscapulohumeral muscular dystrophy (FSHD) expand, initiatives like Project Mercury are addressing key challenges in building international research infrastructure and site readiness. Tune in to hear Dr. Mimi Maeusli explore how global collaboration is accelerating tThe Future of Immunotherapy: Advancing Care in Endometrial Cancer
https://reachmd.com/programs/project-oncology/future-immunotherapy-endometrial-cancer/39932/Immunotherapy is a key treatment option for advanced and recurrent endometrial cancer, yet response rates remain variable—even in patients with mismatch repair-deficient tumors. Hear from Dr. Casey Cosgrove as he explores emerging strategies to enhance immune responsiveness, better predict tr